BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Prithwish has close to 28 years of experience in a Commercial role
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Subscribe To Our Newsletter & Stay Updated
